1. What Happens After an Oral Dose?
An oral dose does not enter the systemic circulation immediately. Instead, the drug must first be released from its dosage form, dissolve in gastrointestinal fluids, cross the intestinal wall, and survive processes that can remove drug before it reaches the systemic circulation.
This is fundamentally different from an intravenous bolus, where the administered dose is placed directly into the systemic circulation. With oral administration, the dose reaching the systemic circulation is generally smaller than the swallowed dose.
An oral dose must pass through several processes before drug reaches the systemic circulation. Absorption and first-pass loss are central determinants of oral bioavailability.
2. What Is Oral Bioavailability?
Bioavailability, commonly denoted by \(F\), describes the fraction of an administered dose that reaches the systemic circulation in an unchanged form, under the definition and conditions relevant to the comparison being made.
For an intravenous dose, systemic availability is conventionally treated as complete, so \(F=1\). For an oral dose, \(F\) is generally less than 1 because drug can be lost during absorption and before reaching the systemic circulation.
Bioavailability is therefore a key bridge between the dose swallowed by a patient and the dose that actually becomes available for systemic disposition.
| Route | Typical conceptual availability | Major presystemic considerations |
|---|---|---|
| IV | \(F=1\) | No gastrointestinal absorption step and no hepatic first-pass loss before systemic entry |
| Oral | \(0<F\leq1\) | Incomplete absorption, intestinal metabolism/efflux, and hepatic first-pass extraction |
| Other extravascular routes | Route dependent | Depends on absorption site, formulation, local metabolism, and route-specific physiology |
3. From the GI Tract to the Systemic Circulation
After an oral dose, several sequential processes determine how much unchanged drug ultimately reaches systemic blood.
- Drug release: the dosage form releases drug into gastrointestinal fluids.
- Dissolution: the drug dissolves sufficiently to become available for absorption.
- Intestinal absorption: drug crosses the intestinal epithelium.
- Intestinal presystemic loss: some drug may be metabolized or transported back into the intestinal lumen.
- Portal delivery: absorbed drug enters the portal circulation and travels toward the liver.
- Hepatic first-pass extraction: the liver may remove or metabolize a fraction before drug reaches the systemic circulation.
- Systemic entry: the surviving fraction becomes available for systemic distribution and elimination.
These processes can be represented conceptually as:
The important point is that absorption and bioavailability are not synonymous. Drug may cross the intestinal wall successfully but still be lost through intestinal or hepatic first-pass processes before reaching the systemic circulation.
4. What Is First-Pass Metabolism?
First-pass metabolism refers to metabolism that occurs after an orally administered drug is absorbed from the gastrointestinal tract but before the drug reaches the systemic circulation.
The liver is particularly important because portal blood carries absorbed drug from the gastrointestinal tract to the liver before it reaches the general systemic circulation.
If the liver extracts a substantial fraction of drug during this first passage, the amount entering systemic circulation can be considerably smaller than the amount absorbed from the gut.
5. Bioavailability Can Be Decomposed Into Components
A useful pharmacokinetic framework separates oral bioavailability into the fraction absorbed and the fractions that survive intestinal and hepatic presystemic loss.
One common conceptual decomposition is:
where:
- \(F_a\) is the fraction of the administered dose that is absorbed across the intestinal wall.
- \(F_g\) is the fraction escaping intestinal presystemic loss.
- \(F_h\) is the fraction escaping hepatic first-pass extraction.
Thus, even if absorption is high, oral bioavailability can be substantially reduced if intestinal or hepatic presystemic extraction is high.
| Component | Question | Potential cause of loss |
|---|---|---|
| \(F_a\) | How much dose crosses the intestinal wall? | Poor dissolution, permeability limitations, degradation, incomplete absorption |
| \(F_g\) | How much absorbed drug survives the intestine? | Intestinal metabolism and efflux transport |
| \(F_h\) | How much portal drug survives the liver? | Hepatic first-pass extraction |
6. Hepatic First-Pass Extraction
Hepatic extraction can be represented using the hepatic extraction ratio, \(E_h\). Conceptually, it is the fraction of drug entering the liver that is removed during a single pass through the organ.
The corresponding fraction escaping hepatic extraction is:
Therefore, if hepatic extraction is 60%, the conceptual hepatic availability is 40%:
This framework helps explain why a drug with substantial hepatic first-pass extraction may have relatively low oral bioavailability even when gastrointestinal absorption is efficient.
7. How Does Hepatic Clearance Relate to First-Pass Extraction?
Hepatic extraction is related to hepatic clearance, but the two quantities are not identical. A commonly used well-stirred hepatic model relates hepatic clearance to hepatic blood flow and the intrinsic ability of the liver to eliminate drug.
where:
- \(CL_h\) = hepatic clearance
- \(Q_h\) = hepatic blood flow
- \(f_u\) = fraction of drug unbound in blood or plasma, depending on the model convention
- \(CL_{\mathrm{int}}\) = intrinsic hepatic clearance
Under the same model, hepatic extraction can be written as:
This relationship shows why hepatic blood flow, protein binding, and intrinsic metabolic capacity can influence first-pass extraction.
8. High- and Low-Extraction Drugs
Hepatic drugs are often discussed using the concepts of high extraction and low extraction. These are useful mechanistic categories, although real drugs exist across a continuum rather than in two perfectly separated groups.
| Feature | Higher hepatic extraction | Lower hepatic extraction |
|---|---|---|
| First-pass effect | Can be substantial | Often smaller |
| Influence of hepatic blood flow | Can be important | Often less dominant |
| Influence of intrinsic clearance | Extraction may approach flow limitation | Changes in intrinsic clearance can have a larger relative effect |
| Oral bioavailability | Can be substantially reduced by hepatic first-pass extraction | May be higher if absorption is also efficient |
The distinction is especially useful when thinking about why changes in physiology, drug interactions, or disease can alter oral exposure.
9. The One-Compartment Oral Dosing Model
A simple oral PK model assumes that drug is absorbed into a single systemic compartment with first-order absorption and first-order elimination.
For an oral dose \(D\), bioavailability \(F\), absorption rate constant \(k_a\), clearance \(CL\), and volume of distribution \(V\), the concentration-time profile can be written as:
where:
This equation contains two competing processes:
- Absorption: controlled by \(k_a\)
- Elimination: controlled by \(k=CL/V\)
The concentration initially rises because absorption adds drug to the systemic compartment. Later, elimination becomes dominant and concentration declines.
10. Oral Dose, Bioavailability, and AUC
Under linear PK and appropriate assumptions, the exposure after an oral dose is related to dose, bioavailability, and clearance:
Compare this with an IV dose:
The factor \(F\) appears for the oral dose because only a fraction of the administered dose becomes systemically available.
11. Bioavailability Does Not Determine Everything
Bioavailability primarily affects the extent of systemic exposure. The absorption rate constant \(k_a\) influences how quickly drug appears in systemic circulation and therefore affects the shape and timing of the concentration-time profile.
Two formulations can have the same overall bioavailability but different absorption rates. Their AUC values may therefore be similar while their \(C_{\max}\) and \(T_{\max}\) differ.
| PK quantity | Primarily reflects |
|---|---|
| AUC | Overall systemic exposure; influenced strongly by \(F\), dose, and clearance |
| Cmax | Peak concentration; influenced by dose, \(F\), absorption rate, distribution, and elimination |
| Tmax | Timing of peak concentration; strongly influenced by absorption and elimination rates |
This distinction is important when interpreting formulation changes. A slower absorption process can change peak concentration and timing without necessarily changing total exposure.
12. How Can Food Affect Oral Pharmacokinetics?
Food can influence oral PK through several mechanisms. The direction and magnitude of the effect depend on the drug, formulation, meal composition, and physiological response.
- Changes in gastric emptying can alter the rate at which drug reaches the small intestine.
- Changes in gastrointestinal fluid volume and composition can affect dissolution.
- Food can alter solubilization of lipophilic drugs.
- Food can interact with transporters or metabolizing enzymes.
- Changes in bile secretion can affect absorption of some compounds.
Consequently, a food effect may appear as a change in \(C_{\max}\), \(T_{\max}\), AUC, or some combination of these quantities.
13. First-Pass Metabolism and Drug Interactions
Oral exposure can be affected by changes in intestinal or hepatic metabolism. An interacting drug may inhibit or induce metabolic enzymes or transport pathways involved in presystemic disposition.
For example, inhibition of an enzyme responsible for intestinal or hepatic metabolism can increase the fraction of an oral dose surviving first-pass metabolism. In a simplified framework, this increases \(F_g\), \(F_h\), or both.
If \(F\) increases while systemic clearance remains unchanged, oral AUC is expected to increase under a linear model:
Importantly, an interaction affecting oral bioavailability is not necessarily equivalent to an interaction affecting systemic clearance. The distinction depends on whether the affected process occurs before or after systemic entry.
14. Worked Example: How First-Pass Metabolism Changes Oral Exposure
Consider a hypothetical drug administered as a 500 mg oral dose. Assume:
- Fraction absorbed: \(F_a=0.80\)
- Fraction escaping intestinal loss: \(F_g=0.75\)
- Fraction escaping hepatic first-pass extraction: \(F_h=0.50\)
- Systemic clearance: \(CL=5\text{ L/h}\)
Step 1: Calculate oral bioavailability
Therefore, the estimated systemic bioavailability is 30%.
Step 2: Calculate the systemically available dose
Although 500 mg was administered orally, the model predicts that approximately 150 mg reaches systemic circulation as unchanged drug.
Step 3: Calculate AUC
Step 4: Compare with an equivalent IV dose
If the same 500 mg were administered intravenously, the simplified IV AUC would be:
Step 5: Compare exposure
Under these assumptions, oral exposure is 30% of exposure from the same administered dose given intravenously.
15. Oral Versus Intravenous Dosing
Comparing oral and IV administration is one of the clearest ways to understand bioavailability.
| Feature | Oral administration | IV administration |
|---|---|---|
| Systemic entry | After absorption and presystemic processes | Direct |
| Bioavailability | Usually \(F<1\) | \(F=1\) by convention |
| First-pass effect | Can be important | Absent before systemic circulation |
| Absorption rate | Determines the input rate into systemic circulation | No absorption step for an IV bolus |
| AUC under linear PK | \(FD/CL\) | \(D/CL\) |
This is why IV administration is often used as a reference when estimating absolute oral bioavailability.
16. How Is Absolute Oral Bioavailability Estimated?
When IV and oral administration of the same drug can be compared appropriately, absolute bioavailability can be estimated from dose-normalized AUC values.
If the oral and IV doses are identical, this simplifies to:
The comparison assumes that the relevant PK conditions allow the AUC ratio to provide an appropriate estimate of systemic availability.
17. How Does Bioavailability Affect Oral Dose Requirements?
In a simplified linear PK model, maintaining the same systemic exposure across routes requires accounting for bioavailability.
Because:
If the target AUC and clearance are fixed, the required administered dose is proportional to \(1/F\):
Therefore, lower oral bioavailability generally requires a larger administered oral dose to achieve the same systemic exposure, assuming the dose-response relationship remains linear and other PK properties are unchanged.
For example, if a drug has \(F=0.25\), then only one quarter of the administered dose is systemically available in this simplified framework. This does not mean that a clinical dose should automatically be increased fourfold; real dose selection also depends on safety, therapeutic index, nonlinear PK, formulation, variability, and clinical evidence.
18. Oral Dosing at Steady State
For repeated oral dosing under linear PK, bioavailability influences the amount of drug entering the systemic circulation with each dose.
The average steady-state concentration over a dosing interval can be represented as:
where \(\tau\) is the dosing interval.
This equation shows the basic relationship among bioavailability, dose, clearance, and dosing frequency.
| Change | Expected effect on average steady-state concentration |
|---|---|
| Increase \(F\) | Increase exposure |
| Increase dose \(D\) | Increase exposure |
| Increase clearance \(CL\) | Decrease exposure |
| Increase dosing interval \(\tau\) | Decrease average concentration |
19. What If PK Is Nonlinear?
The equations presented above assume linear pharmacokinetics over the relevant dose range. In linear PK, exposure changes proportionally with dose and parameters such as clearance and bioavailability can be treated as approximately constant.
Real drugs can exhibit nonlinear behavior. Examples include:
- Saturable metabolic pathways
- Saturable transport
- Capacity-limited absorption
- Dose-dependent bioavailability
- Concentration-dependent protein binding
- Time-dependent induction or inhibition of metabolic pathways
Under nonlinear PK, doubling the oral dose does not necessarily double AUC. The relationship \[ AUC=\frac{FD}{CL} \] may no longer provide an adequate description if \(F\) or \(CL\) changes with dose or concentration.
20. Why Can Oral Bioavailability Vary Between Patients?
Oral bioavailability can vary because multiple processes occur before systemic circulation is reached. Differences among patients can therefore arise from gastrointestinal physiology, formulation handling, enzyme activity, transporter activity, hepatic function, and interacting medications.
| Factor | Potential PK consequence |
|---|---|
| Gastric emptying | Can alter the rate at which drug reaches the absorption site |
| Intestinal enzyme activity | Can affect \(F_g\) |
| Transporter activity | Can influence absorption and intestinal loss |
| Hepatic blood flow | Can influence extraction for flow-sensitive drugs |
| Intrinsic hepatic clearance | Can affect hepatic extraction and systemic clearance |
| Protein binding | Can influence hepatic disposition depending on the drug and model |
| Drug interactions | Can alter metabolism or transport and therefore oral exposure |
Population PK models can incorporate such sources of variability when appropriate data are available, although a mechanistic explanation for a covariate relationship requires more than simply observing statistical association.
21. Common Misunderstandings About Oral Dosing
Mistake 1: Treating the oral dose as the systemic dose
A 500 mg oral dose does not imply that 500 mg immediately reaches systemic circulation. Bioavailability determines the systemically available fraction.
Mistake 2: Equating absorption with bioavailability
A drug can be absorbed efficiently but still have low oral bioavailability if substantial intestinal or hepatic first-pass loss occurs.
Mistake 3: Treating first-pass metabolism as total hepatic metabolism
First-pass metabolism occurs before systemic circulation. Hepatic metabolism after systemic entry contributes to systemic clearance but is not itself a first-pass event.
Mistake 4: Assuming bioavailability determines \(T_{\max}\)
Bioavailability primarily determines the extent of exposure. Absorption rate, represented in a simple model by \(k_a\), is a major determinant of the timing of the peak.
Mistake 5: Applying linear PK equations automatically
Relationships such as \(AUC=FD/CL\) depend on assumptions about linearity and the stability of \(F\) and \(CL\).
22. How Oral Dosing Enters a PK Model
In a PK model, oral dosing is commonly represented as an input process rather than an instantaneous systemic dose.
In a simple oral model, drug enters a depot or absorption compartment and is transferred into the systemic compartment according to the assumed absorption process.
More sophisticated models can represent transit compartments, delayed absorption, parallel absorption pathways, formulation effects, enterohepatic recirculation, saturable absorption, or mechanistic gut and liver models.
23. A Practical Workflow for Interpreting Oral PK
- Identify the route and dose. Determine whether the drug was administered orally, intravenously, or by another route.
- Examine the concentration-time profile. Look for the absorption phase, peak concentration, and elimination phase.
- Consider bioavailability. Ask what fraction of the administered dose is expected to reach systemic circulation.
- Separate absorption from first-pass loss. Distinguish incomplete absorption from intestinal and hepatic presystemic extraction.
- Consider clearance. Once drug reaches systemic circulation, systemic clearance determines how rapidly exposure is removed.
- Evaluate food and formulation effects. Determine whether changes affect the rate, extent, or both.
- Consider interactions. Ask whether enzymes or transporters affecting oral availability or systemic clearance may be altered.
- Check the assumptions. Confirm whether a linear one-compartment framework is adequate for the scientific question.
24. Key Takeaways
- An oral dose must be absorbed before drug can enter systemic circulation.
- Oral bioavailability \(F\) describes the fraction of an administered dose that reaches systemic circulation in an appropriate unchanged form.
- Bioavailability can be conceptually decomposed as \(F=F_aF_gF_h\), representing absorption and survival of intestinal and hepatic presystemic loss.
- First-pass metabolism occurs before drug reaches systemic circulation and is therefore distinct from systemic hepatic clearance.
- Hepatic extraction is influenced by hepatic blood flow, protein binding, and intrinsic hepatic clearance within commonly used hepatic models.
- Under linear PK, oral exposure is related to dose, bioavailability, and clearance through \(AUC=FD/CL\).
- Bioavailability primarily affects the extent of systemic exposure, whereas absorption rate strongly influences the timing and magnitude of the concentration peak.
- Food, formulation, enzyme activity, transporters, hepatic physiology, and drug interactions can all affect oral PK.
- The same oral dose can produce different systemic exposures when bioavailability or clearance differs.
- Simple equations such as \(AUC=FD/CL\) depend on assumptions about linearity and parameter stability.
- Mechanistic decomposition of bioavailability is useful for understanding oral PK, but individual components such as \(F_a\), \(F_g\), and \(F_h\) are not automatically identifiable from routine clinical concentration data.
Where to Go Next
A natural progression from oral dosing and first-pass metabolism is to study the one-compartment oral PK model in greater detail, including derivation of the concentration-time equation, \(C_{\max}\), \(T_{\max}\), AUC, accumulation, and repeated dosing.
From there, useful next topics include oral absorption models, flip-flop kinetics, nonlinear oral PK, food effects, hepatic clearance models, drug-drug interactions, and population PK modeling.